- Home
- About Us
- Service
- Application
- Technology
- Contact Us
HapOnco® Basic Panel
HapOnco® Basic Panel
HapOnco<sup>®</sup> BasicPanel™ NGS Assays
HapOnco® Lung Cancer BasicPanel™ NGS Assay
Product Overview
HapOnco® Lung Cancer BasicPanel™ NGS Assay is an NGS-based assay for lung cancer patients to guide therapy selection. It detects 11 lung cancer-related genes, including 8 NCCN-recommended targetable driver genes and 3 genes critical to lung cancer development, as well as 29 SNP loci associated with chemotherapy responses and side effects. The HapOnco® Lung Cancer BasicPanel™ NGS Assay focuses on the sensitivity of essential targeted drugs and can offer comprehensive reference data for targeted treatments and prognostic assessments for lung cancer patients.
Applicable Population
Patients with lung cancer seeking targeted precision treatment or resistance evaluation.
HapOnco® Colorectal Cancer BasicPanel™ NGS Assay
Product Overview
HapOnco® Colorectal Cancer BasicPanel™ NGS Assay covers 23 genes relating to the efficacy of targeted therapies for colorectal cancer, including the entire protein-coding regions of all driver genes with targetable mutations as recommended by NCCN (23 genes) and 7 fusion variants. The gene panel of this assay also includes 25 SNP loci related to chemotherapy responses and side effects. HapOnco® Colorectal Cancer BasicPanel™ NGS Assay provides comprehensive guidance for clinical use in terms of targeted therapy and prognosis assessment.
Applicable Population
Patients with colorectal cancer seeking targeted precision treatment or resistance evaluation.
Address
Units 610, 6/F, Building 16W, Phase 3, HongKong Science Park, New Territories, HongKong
Phone
+852 69410851
customer_service@haplox.net
© Copyright Job Portal 2025.
